Skip to content
Company Terminals IPO Intel Calculators Gold Desk Research Roadmap Pricing Get started →
The $13 Billion Machine: Inside the Macro-Economics of the 2026 FIFA World CupAlibaba share price is up 16% today. what next for Baba stock?IPO Allotment status check online by PAN number 2025UnitedHealth (UNH Stock): You should stay away from itQ4 results live updates: Adani Group companies in focusThe $13 Billion Machine: Inside the Macro-Economics of the 2026 FIFA World CupAlibaba share price is up 16% today. what next for Baba stock?IPO Allotment status check online by PAN number 2025UnitedHealth (UNH Stock): You should stay away from itQ4 results live updates: Adani Group companies in focus

Max Healthcare Institute

MAXHEALTH · Healthcare Facilities · INE027H01010

Analyst mean 2.20 · 25 analysts · 50% bullish
₹1,112.00
Close 2026-07-31 · Balanced risk

Reading the Statements forensic interpretation

What the numbers mean when read together — computed from the filings, not a score.

Operating cash flow backs the profit

Operating cash flow is 113% of trailing profit — the earnings are converting to cash, not just accruals.

Full read

Last operating cash flow ₹1,633 cr against trailing net profit ₹1,442 cr. A ratio at or above ~0.9 means reported profit is showing up as real cash.

Profit growing with revenue

Both revenue and profit grew over the last year (19.2% and 34%) — growth is translating to the bottom line.

Full read

Trailing revenue ₹8,374 cr, trailing profit ₹1,442 cr. Profit growing at least as fast as revenue indicates operating leverage or pricing power.

Free cash flow is variable

Free cash flow swings between positive and negative across the cycle.

Full read

Latest ₹165 cr, negative in 2 of 10 years.

Borrowing while holding investments

Borrowings rose 168% over two years while the company also carries ₹5 cr in investments. Why borrow at interest while parking money elsewhere is a fair question.

Full read

Borrowings moved to ₹3,478 cr from ₹1,299 cr. Simultaneous large investments can be legitimate treasury management, or a sign that reported cash is not freely available.

Price & Valuation 10-year, split-adjusted

Markers show corporate actions (splits, bonus, dividends). Prices are split-adjusted so the series is continuous.

Valuation & Quality

Valuation
P/E (TTM) 64.8x
P/B 10x
P/S 12.84x
PEG 8
P/FCF 33920.3x
Dividend Yield 0.18%
Leverage
Debt / Equity conservative 0.32
Payout Ratio 13.5%
Returns & Margins
Operating Margin (TTM) 20.9%
Net Margin (TTM) 17.2%
Return on Equity 14.3%
Return on Assets 8.9%
Implied Growth (Graham) growth the market is pricing in 28.2%
Rule of 40 33.1
Growth 12.2% + Margin 20.9% — below 40

Ownership & Skin in the Game

Promoter23.71% ▲ 0.00
FII41.78%
DII
Mutual Funds18.68%

Quarterly Financials ₹ cr

MetricJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue1,5431,7071,8681,9102,0282,1352,0682,143
Expenses1,1561,2571,3691,3981,5051,5601,5291,536
Other Income3541-40473733-348
Depreciation778498101104108111123
Profit before tax321374309402400446365465
Net Profit236282239319308491301342
EPS2.432.902.463.283.175.053.093.52

Balance Sheet ₹ cr, annual

ItemMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital966970971972972973
Reserves4,6735,3136,4397,4368,4099,774
Borrowings1,1019136891,2993,0103,478
Fixed Assets6,5367,0187,0398,78411,50212,991
CWIP27151252553901593
Investments111235
Total Assets8,5439,18910,10212,00015,18617,184
DISCLAIMER: FinMinutes is a financial data and analytics platform, not a SEBI-registered investment adviser. Everything here is for educational and informational purposes. Forensic interpretations are computed from disclosed data and are not recommendations. Do your own due diligence.